Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity-Reference-Cited by-同舟云学术

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

Published:2021-12-03 Issue:49 Volume:143 Page:20697-20709
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Ma Chunlong¹,Xia Zilei¹,Sacco Michael Dominic²,Hu Yanmei¹,Townsend Julia Alma³,Meng Xiangzhi⁴,Choza Juliana¹,Tan Haozhou¹,Jang Janice¹,Gongora Maura V.²,Zhang Xiujun²,Zhang Fushun⁴,Xiang Yan⁴,Marty Michael Thomas³^ORCID,Chen Yu²,Wang Jun¹^ORCID

Affiliation:

1. Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States

2. Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612, United States

3. Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States

4. Department of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States

Funder

Arizona Department of Health Services

National Institute of Allergy and Infectious Diseases

University of Texas Health Science Center at San Antonio

Publisher

American Chemical Society (ACS)

Subject

Colloid and Surface Chemistry,Biochemistry,General Chemistry,Catalysis

Link

https://pubs.acs.org/doi/pdf/10.1021/jacs.1c08060

Reference40 articles.

1. SARS-CoV-2 variants, spike mutations and immune escape